Galapagos NV GLPG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLPG is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients’ lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,123
- Website
- https://www.glpg.com
Comparables
Valuation
|
Metric
|
GLPG
|
QURE
|
ENTA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.85 | 1.05 | 1.36 |
Price/Sales | 3.34 | 13.72 | 3.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
GLPG
QURE
ENTA
Financial Strength
|
Metric
|
GLPG
|
QURE
|
ENTA
|
|---|---|---|---|
Quick Ratio | 8.76 | 8.44 | 6.04 |
Current Ratio | 9.02 | 8.85 | 6.25 |
Interest Coverage | −40.80 | −6.85 | — |
Quick Ratio
GLPG
QURE
ENTA
Profitability
|
Metric
|
GLPG
|
QURE
|
ENTA
|
|---|---|---|---|
Return on Assets (Normalized) | 0.17% | −35.54% | −27.96% |
Return on Equity (Normalized) | 0.29% | −82.34% | −47.34% |
Return on Invested Capital (Normalized) | −1.92% | −55.12% | −44.45% |
Return on Assets
GLPG
QURE
ENTA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hhkhvbfm | Tky | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jfhdfhkz | Nfjdqc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sgqlfkck | Fbbsgw | $97.8 Bil | |
MRNA
| Moderna Inc | Hbjklzgl | Nlz | $41.3 Bil | |
ARGX
| argenx SE ADR | Qrsgzksc | Zmrgq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rrggvpbf | Bwcv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rybzmkbq | Xbwspz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dpqllgwgy | Ffkgq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fpfvhptdv | Gdvwpp | $12.5 Bil | |
INCY
| Incyte Corp | Trlsvmpr | Rfxcy | $11.6 Bil |